ABSTRACT
Toasting time (TT) of rapeseed meal (RSM), the diet processing (DP) method and the interaction between both on the apparent CP digestion along the gastrointestinal tract and the apparent ileal digestibility (AID) of amino acids of growing pigs were investigated. The experiment consisted of a 3×3 factorial design of TT of RSM (0, 60 and 120 min) and DP method (mash, pelleting and extrusion). In total, 81 boars with a starting BW of 20 kg were euthanized 4 h after their last feeding. The gastrointestinal tract was dissected and the small intestine divided in three sections of similar length. Samples were collected from the stomach, 1.5 m from the ends of each of the three sections of the small intestine, and the rectum. The apparent digestibility (AD) of CP for each of the small intestine sections was used to calculate the rate of CP digestion. Increasing the TT of RSM resulted in lower protein solubility, lower lysine/reactive lysine contents and higher protein denaturation, indicative of the occurrence of protein aggregation and Maillard reactions. There were significant effects (P⩽0.01) of TT on the AD of CP in the different sections of the gastrointestinal tract. The rate of CP digestion of the 0 min toasted RSM diets was 23% and 35% higher than that of the 60 and 120 min toasted RSM diets, respectively. There was a significant interaction (P=0.04) between TT and DP for the AID of CP. Although pelleting of the 0 and 60 min toasted RSM diets did not change the AID of CP with respect to the mash diets, pelleting of the 120 min toasted RSM diet increased the AID of CP by 9.3% units. Extrusion increased the AID of CP of the 0 and 60 min toasted RSM diets by 3.4% and 4.3% units with respect to the mash diets, whereas extrusion of the 120 min toasted RSM diet increased the AID of CP by 6.9% units. Similar positive effects of pelleting and extrusion were obtained for the AID of lysine and reactive lysine, especially in the diets with higher TT. In conclusion, processing (pelleting and extrusion) of RSM containing diets can ameliorate the negative effects of RSM toasting on protein and amino acid digestibility; these effects were larger for the RSM toasted for longer times.
Subject(s)
Animal Feed/analysis , Swine/physiology , Amino Acids/metabolism , Animal Nutritional Physiological Phenomena , Animals , Brassica rapa/chemistry , Diet/veterinary , Digestion , Maillard Reaction , Male , Swine/growth & developmentABSTRACT
Four experiments were carried out to study the possible differences in metabolizable energy (ME) of meals (RSM) or expeller meals (RSE) from double-low rapeseed (Expt. 1), the influence of processing on ME (Expt. 2) and on relative phosphorus (P) bioavailability (Expt. 3) in RSM, and effect of RSM inclusion on growth performance of broilers (Expt. 4). For Expt. 1, diets with 300 g/kg RSM from 11 RSM and 4 RSE varieties were fed to broilers from d 14 to 21, with excreta collection on d 19 to 21. Each treatment had 8 replicates and 3 birds per replicate. Energy metabolizability of RSM of a specialized high glucosinolate variety (V275OL) was greater (P < 0.05) than all the other varieties. In Expt. 2, two RSM varieties were processed with mild or conventional processing condition. There were no variety effects on ME, but ME and MEn were greater (P < 0.01) for RSM processed by mild processing condition. In Expt. 3, P bioavailability of RSM was determined, relative to MSP, using growth performance and tibia ash as responses. Phosphorus relative bioavailability values were greater (P < 0.05) in RSM of DK Cabernet variety processed using the mild processing condition. In Expt. 4, two RSM varieties were added to wheat-soybean meal-based diet at the rates of 50, 100, 150, or 200 g/kg and fed to broilers from d 0 to 42. Inclusion of 150 and 200 g/kg of RSM resulted in reduced weight gain and increased feed conversion ratio (FCR) compared (P < 0.01) with the lower inclusion levels during the starter phase. For the entire trial (d 0 to 42), weight gain was greater (P < 0.01) for birds receiving diets with RSM from PR46W21 variety. It was concluded from the experiments that apart from the residual ether extract content, variety differences had no impact on ME of RSM, conventional processing reduced ME and relative bio-availability of P; and that the maximum level of RSM inclusion depends on maximum growth performance level desired.
Subject(s)
Brassica napus/chemistry , Chickens/growth & development , Chickens/metabolism , Nutritive Value , Phosphorus/metabolism , Animal Feed/analysis , Animal Nutritional Physiological Phenomena/drug effects , Animals , Biological Availability , Diet/veterinary , Dietary Supplements/analysis , Energy Metabolism/drug effects , Male , Random AllocationSubject(s)
Idiopathic Pulmonary Fibrosis/diagnosis , Idiopathic Pulmonary Fibrosis/therapy , Pulmonary Medicine/methods , Pulmonary Medicine/trends , Algorithms , Biopsy , Diagnosis, Differential , Evidence-Based Practice/standards , Evidence-Based Practice/trends , France , Humans , Lung/pathology , Pulmonary Medicine/standards , Radiography, Thoracic , Tomography, X-Ray ComputedSubject(s)
Idiopathic Pulmonary Fibrosis/diagnosis , Idiopathic Pulmonary Fibrosis/therapy , Pulmonary Medicine/methods , Pulmonary Medicine/trends , Algorithms , Biopsy , Bronchoalveolar Lavage , Diagnosis, Differential , Evidence-Based Practice/standards , Evidence-Based Practice/trends , France , Humans , Lung/pathology , Pulmonary Medicine/standards , Radiography, Thoracic , Tomography, X-Ray ComputedSubject(s)
Idiopathic Pulmonary Fibrosis/diagnosis , Idiopathic Pulmonary Fibrosis/therapy , Pulmonary Medicine/methods , Pulmonary Medicine/trends , Algorithms , Biopsy , Bronchoalveolar Lavage , Diagnosis, Differential , Evidence-Based Practice/standards , Evidence-Based Practice/trends , France , Humans , Lung/pathology , Pulmonary Medicine/standards , Radiography, Thoracic , Tomography, X-Ray ComputedSubject(s)
Idiopathic Pulmonary Fibrosis/diagnosis , Idiopathic Pulmonary Fibrosis/therapy , Acetylcysteine/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Antibodies/therapeutic use , Anticoagulants/therapeutic use , Colchicine/therapeutic use , Diagnostic Techniques, Respiratory System , France , Genetic Testing , Humans , Idiopathic Pulmonary Fibrosis/genetics , Interdisciplinary Communication , Patient Care Team , VaccinationABSTRACT
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is underdiagnosed because of limited disease awareness with trivialization of the symptoms in the general population. METHODS: A survey was conducted in a representative sample (n=2758) of individuals older than 40 years of age in the general population of France. Respiratory symptoms and knowledge about COPD were assessed in individuals with or at risk for COPD (n=860, 31% of the sample). RESULTS: In the overall sample, 40% of individuals had a Medical Research Council dyspnea grade of 1 or more but only 9% spontaneously reported shortness of breath. Of these 9%, 72% reported limitations to their daily activities but only 14% believed they had severe lung disease. In the overall sample, only 220 (8%) individuals knew the term COPD and only 66% associated the term COPD with respiratory disease. CONCLUSIONS: Despite a large proportion of individuals at risk for COPD or having COPD and a high prevalence of breathlessness, awareness of respiratory symptoms and knowledge of COPD were limited. These findings indicate a need for educating the general population about COPD.
Subject(s)
Pulmonary Disease, Chronic Obstructive/epidemiology , Adult , Aged , Dyspnea/epidemiology , Female , France/epidemiology , Health Behavior , Health Education , Health Surveys , Humans , Interviews as Topic , Knowledge , Male , Middle Aged , Prevalence , Pulmonary Disease, Chronic Obstructive/psychology , Risk , Sampling Studies , Smoking/epidemiology , Socioeconomic Factors , Surveys and Questionnaires , Vulnerable PopulationsABSTRACT
Classification of chronic obstructive pulmonary disease (COPD) is usually based on the severity of airflow limitation, which may not reflect phenotypic heterogeneity. Here, we sought to identify COPD phenotypes using multiple clinical variables. COPD subjects recruited in a French multicentre cohort were characterised using a standardised process. Principal component analysis (PCA) was performed using eight variables selected for their relevance to COPD: age, cumulative smoking, forced expiratory volume in 1 s (FEV(1)) (% predicted), body mass index, exacerbations, dyspnoea (modified Medical Research Council scale), health status (St George's Respiratory Questionnaire) and depressive symptoms (hospital anxiety and depression scale). Patient classification was performed using cluster analysis based on PCA-transformed data. 322 COPD subjects were analysed: 77% were male; median (interquartile range) age was 65.0 (58.0-73.0) yrs; FEV(1) was 48.9 (34.1-66.3)% pred; and 21, 135, 107 and 59 subjects were classified in Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 1, 2, 3 and 4, respectively. PCA showed that three independent components accounted for 61% of variance. PCA-based cluster analysis resulted in the classification of subjects into four clinical phenotypes that could not be identified using GOLD classification. Importantly, subjects with comparable airflow limitation (FEV(1)) belonged to different phenotypes and had marked differences in age, symptoms, comorbidities and predicted mortality. These analyses underscore the need for novel multidimensional COPD classification for improving patient care and quality of clinical trials.
Subject(s)
Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/therapy , Aged , Cluster Analysis , Comorbidity , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Phenotype , Principal Component Analysis , Pulmonary Disease, Chronic Obstructive/classification , Pulmonary Medicine/methods , Research DesignSubject(s)
Alveolitis, Extrinsic Allergic/etiology , Dacarbazine/analogs & derivatives , Lung Diseases, Interstitial/etiology , Pulmonary Fibrosis/etiology , Biopsy , Brain/radiation effects , Dacarbazine/adverse effects , Dyspnea/etiology , Humans , Lung/pathology , Lymphocytes/metabolism , Middle Aged , Prednisone/therapeutic use , TemozolomideABSTRACT
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is markedly under-diagnosed, which may relate to under-reporting of symptoms and poor awareness of the disease. METHODS: A survey was conducted in a sample of the French general population aged 40-75 years (n=2758) to assess respiratory symptoms and level of knowledge of the disease in subjects with or at-risk of COPD (n=860, 31%). RESULTS: The high frequency of dyspnoea (MRC dyspnoea grade > or =1: 40%) contrasted with that of subjects spontaneously reporting respiratory problems (9%). Among these, 72% reported limitations in daily-life activities but only 14% considered that they were severely affected by their respiratory status. A very low proportion of subjects knew the term COPD (8%) and only 66% of these associated COPD with a respiratory disease. CONCLUSIONS: There is a wide gap between the high number of subjects at risk of COPD in the general population and the frequency of breathlessness in these subjects on one hand, and the poor knowledge of the disease, poor perception of symptoms, and under-diagnosis and under-use of spirometry on the other. Increasing awareness of COPD in the population is needed.
Subject(s)
Awareness , Health Knowledge, Attitudes, Practice , Pulmonary Disease, Chronic Obstructive/diagnosis , Adult , Aged , Cough/etiology , Dyspnea/etiology , Female , Health Surveys , Humans , Incidence , Male , Middle Aged , Paris/epidemiology , Pulmonary Disease, Chronic Obstructive/complications , Pulmonary Disease, Chronic Obstructive/epidemiology , Risk Factors , Sampling Studies , Severity of Illness Index , Smoking/adverse effects , Spirometry , Surveys and QuestionnairesSubject(s)
Physician-Patient Relations , Smoking Prevention , Humans , Motivation , Smoking/psychology , Smoking CessationABSTRACT
INTRODUCTION: Temozolomide is an alkylating agent approved for treatment of glioblastoma in association with radiotherapy. CASE REPORT: We report the case of a 56 year old woman presenting with alveolo-interstitial pneumonia after treatment with Temozolomide. Initially she received induction treatment with Temozolomide and concomitant radiotherapy for bifocal high grade glioblastoma. A month later she received, as scheduled, the first course of Temozolomide maintenance chemotherapy. Grade II dyspnoea developed a few days later. High resolution computed tomography showed alveolo-interstitial opacities with basal predominance, associated with alveolar nodules. Broncho-alveolar lavage showed a lymphocytosis. No bacteria were isolated from microbiological samples. A final diagnosis of drug-induced pneumonia was based on the time sequence and absence of other causes. CONCLUSION: There is little literature concerning the pulmonary toxicity of Temozolomide. However, our case report of drug-induced pneumonia and similar observations in the databases of regional pharmacovigilance centres suggest that this side effect should be included in the summary of product characteristics.